Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Filings indexed 844 across all filing types
Latest filing 2026-01-05 Director's Dealing
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2026
Director's Dealing
2026-01-05 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English
Director's Dealing 2025
Director's Dealing
2025-12-04 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-13 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2025, by Aclaris Therapeutics, Inc. It announces the issuance of a press release containing financial results for the quarter and nine months ended September 30, 2025. The text explicitly states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of Section 18, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3850 characters, which is relatively short and consistent with a current report announcing earnings rather than containing detailed financial statements. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to an Earnings Release announcement. Therefore, this document is best classified as an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.